PEDIATRICS Vol. 85 No. 4 April 1990, pp. 648-650
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, K. S.
Right arrow Articles by Steinberg, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, K. S.
Right arrow Articles by Steinberg, E. A.

Comparative Immune Responses to Haemophilus influenzae Type b Polysaccharide and a Polysaccharide-Protein Conjugate Vaccine

Kwang Sik Kim MD1, Victor K. Wong MD1, Robert Adler MD1, and Evan A. Steinberg MD1

1 From the Department of Pediatrics, Childrens Hospital of Los Angeles and the University of Southern California School of Medicine, and Kaiser Foundation Hospital, Los Angeles

Haemophilus influenzae type b is the most common cause of bacterial meningitis in children in the United States. Antibody to the capsular polysaccharide of this organism, polyribosylribitol-phosphate (PRP), is important in protecting against invasive disease. In 1985, H influenzae type b vaccine containing only PRP was licensed in the United States for use in children 24 to 59 months of age.

Studies conducted in the United States and Finland have shown that PRP vaccine is safe and immunogenic in children older than 18 months of age.1,2 In Finland, an efficacy of approximately 80% was obtained when PRP vaccine was used to prevent invasive disease caused by H influenzae type b in children older than 24 months of age.3 The immunogenicity of the PRP vaccine in children 18 to 23 months of age, however, was not clearly established. Reported rates of seroconversion after receipt of a single dose of PRP vaccine ranged from 20% to 75%1.3-5

The purpose of our studies was to evaluate the immunogenicity y of PRP vaccines and of conjugate vaccine (PRP-Neisseria meningitidis outer membrane protein complex [PRP-OMPC]) in children from the Los Angeles area.

First, we conducted a randomized, prospective study to compare the immunogenicity of the PRP vaccines produced by three manufacturers. A total of 147 healthy children between the ages of 18 and 58 months were recruited from Childrens Hospital of Los Angeles and Kaiser Foundation Hospital, Los Angeles, to receive, according to a prepared randomization schedule, 25 µg of the following PRP vaccines: Hib-Immune, lot 184-669, 190-654; Hib-Vax, lot 7L91071, 7D91043; or b-CAPSA I, lot M087BD, M068BC.